Panel urges FDA to remove warnings on hormonal menopause therapy
BioPharma Dive
JULY 18, 2025
The study was stopped early in 2002 after researchers observed an increased risk of breast cancer and heart disease. During the meeting, Rachel Rubin, an assistant clinical professor in urology at Georgetown University Hospital and an adviser to Let’s Talk Menopause, urged the FDA to remove the box label. TechTarget, Inc.s
Let's personalize your content